TY - JOUR
T1 - Repeated treatment with cannabidiol but not Δ9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance
AU - Hayakawa, Kazuhide
AU - Mishima, Kenichi
AU - Nozako, Masanori
AU - Ogata, Ayumi
AU - Hazekawa, Mai
AU - Liu, An Xin
AU - Fujioka, Masayuki
AU - Abe, Kohji
AU - Hasebe, Nobuyoshi
AU - Egashira, Nobuaki
AU - Iwasaki, Katsunori
AU - Fujiwara, Michihiro
N1 - Funding Information:
Part of this study was supported by a Grant-in-Aid for Scientific Research (No. 17590479) from the Ministry of Education, Science and Culture of Japan and the Advanced Materials Institute of Fukuoka University and The Naito Foundation.
PY - 2007/3
Y1 - 2007/3
N2 - Both Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol are known to have a neuroprotective effect against cerebral ischemia. We examined whether repeated treatment with both drugs led to tolerance of their neuroprotective effects in mice subjected to 4 h-middle cerebral artery (MCA) occlusion. The neuroprotective effect of Δ9-THC but not cannabidiol was inhibited by SR141716, cannabinoid CB1 receptor antagonist. Fourteen-day repeated treatment with Δ9-THC, but not cannabidiol, led to tolerance of the neuroprotective and hypothermic effects. In addition, repeated treatment with Δ9-THC reversed the increase in cerebral blood flow (CBF), while cannabidiol did not reverse that effect. Repeated treatment with Δ9-THC caused CB1 receptor desensitization and down-regulation in MCA occluded mice. On the contrary, cannabidiol did not influence these effects. Moreover, the neuroprotective effect and an increase in CBF induced by repeated treatment with cannabidiol were in part inhibited by WAY100135, serotonin 5-HT1A receptor antagonist. Cannabidiol exhibited stronger antioxidative power than Δ9-THC in an in vitro study using the 1,1-diphenyl-2-picryhydrazyl (DPPH) radical. Thus, cannabidiol is a potent antioxidant agent without developing tolerance to its neuroprotective effect, acting through a CB1 receptor-independent mechanism. It is to be hoped that cannabidiol will have a palliative action and open new therapeutic possibilities for treating cerebrovascular disorders.
AB - Both Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol are known to have a neuroprotective effect against cerebral ischemia. We examined whether repeated treatment with both drugs led to tolerance of their neuroprotective effects in mice subjected to 4 h-middle cerebral artery (MCA) occlusion. The neuroprotective effect of Δ9-THC but not cannabidiol was inhibited by SR141716, cannabinoid CB1 receptor antagonist. Fourteen-day repeated treatment with Δ9-THC, but not cannabidiol, led to tolerance of the neuroprotective and hypothermic effects. In addition, repeated treatment with Δ9-THC reversed the increase in cerebral blood flow (CBF), while cannabidiol did not reverse that effect. Repeated treatment with Δ9-THC caused CB1 receptor desensitization and down-regulation in MCA occluded mice. On the contrary, cannabidiol did not influence these effects. Moreover, the neuroprotective effect and an increase in CBF induced by repeated treatment with cannabidiol were in part inhibited by WAY100135, serotonin 5-HT1A receptor antagonist. Cannabidiol exhibited stronger antioxidative power than Δ9-THC in an in vitro study using the 1,1-diphenyl-2-picryhydrazyl (DPPH) radical. Thus, cannabidiol is a potent antioxidant agent without developing tolerance to its neuroprotective effect, acting through a CB1 receptor-independent mechanism. It is to be hoped that cannabidiol will have a palliative action and open new therapeutic possibilities for treating cerebrovascular disorders.
UR - http://www.scopus.com/inward/record.url?scp=33847261953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847261953&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2006.11.005
DO - 10.1016/j.neuropharm.2006.11.005
M3 - Article
C2 - 17320118
AN - SCOPUS:33847261953
SN - 0028-3908
VL - 52
SP - 1079
EP - 1087
JO - Neuropharmacology
JF - Neuropharmacology
IS - 4
ER -